
News|Articles|March 1, 2005
Exenatide: A novel incretin mimetic hormone for the treatment of type 2 diabetes
A number of clinical approaches are utilized in managing the overlapping aspects of poor glycemic control in patients with type 2 diabetes. Exenatide (Amylin/Lilly), a novel drug in a new medication class known as the incretin mimetic agents, offers a new mechanism to achieve glycemic control.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicaid Unwinding Drops Coverage for Millions but Uninsured Rate Remains Steady
2
Expert Discussion on Safety Results of Guselkumab for Crohn’s Disease
3
AI Crucial Tool for Patient Management, Lowering Readmission Risk, Expert Says
4
Signals of Change: How Biomarkers Are Reshaping Oncology and Healthcare Delivery
5